Fisher R A, Robertson S M, Olson M S
J Biol Chem. 1987 Apr 5;262(10):4631-8.
Infusion of the thromboxane A2 analogue U-46619 into isolated perfused rat livers resulted in dose-dependent increases in glucose output and portal vein pressure, indicative of constriction of the hepatic vasculature. At low concentrations, e.g. less than or equal to 42 ng/ml, glucose output occurred only during agonist infusion; whereas at concentrations greater than or equal to 63 ng/ml, a peak of glucose output also was observed upon termination of agonist infusion coincident with relief of hepatic vasoconstriction. Effluent perfusate lactate/pyruvate and beta-hydroxybutyrate/acetoacetate ratios increased significantly in response to U-46619 infusion. Hepatic oxygen consumption increased at low U-46619 concentrations (less than or equal to 20 ng/ml) and became biphasic with a transient spike of increased consumption followed by a prolonged decrease in consumption at higher concentrations. Increased glucose output in response to 42 ng/ml U-46619 was associated with a rapid activation of glycogen phosphorylase, slight increases in tissue ADP levels, and no increase in cAMP. At 1000 ng/ml, U-46619 activation of glycogen phosphorylase was accompanied by significant increases in tissue levels of AMP and ADP, decreases in ATP, and slight increases in cAMP. In isolated hepatocytes, U-46619 did not stimulate glucose output or activate glycogen phosphorylase. Reducing the perfusate calcium concentration from 1.25 to 0.05 mM resulted in a marked reduction of the glycogenolytic response to U-46619 (42 ng/ml) with no efflux of calcium from the liver. U-46619-induced glucose output and vasoconstriction displayed a similar dose dependence upon the perfusate calcium concentration. Thus, U-46619 exerts a potent agonist effect on glycogenolysis and vasoconstriction in the perfused rat liver. The present findings support the concept that U-46619 stimulates hepatic glycogenolysis indirectly via vasoconstriction-induced hypoxia within the liver.
将血栓素A2类似物U - 46619注入离体灌注大鼠肝脏,可导致葡萄糖输出量和门静脉压力呈剂量依赖性增加,这表明肝血管系统发生了收缩。在低浓度时,例如小于或等于42 ng/ml,葡萄糖输出仅在激动剂输注期间出现;而在浓度大于或等于63 ng/ml时,在激动剂输注终止且肝血管收缩缓解时,也观察到了葡萄糖输出峰值。灌注流出液中的乳酸/丙酮酸和β - 羟基丁酸/乙酰乙酸比值在输注U - 46619后显著增加。在低U - 46619浓度(小于或等于20 ng/ml)时,肝脏耗氧量增加,且呈双相变化,先是短暂的耗氧量增加峰值,随后在较高浓度时耗氧量持续下降。对42 ng/ml U - 46619的反应中,葡萄糖输出增加与糖原磷酸化酶的快速激活、组织ADP水平略有升高以及cAMP无增加有关。在1000 ng/ml时,U - 46619对糖原磷酸化酶的激活伴随着组织中AMP和ADP水平的显著增加、ATP水平的降低以及cAMP的轻微增加。在分离的肝细胞中,U - 46619不刺激葡萄糖输出或激活糖原磷酸化酶。将灌注液钙浓度从1.25 mM降至0.05 mM,可显著降低对U - 46619(42 ng/ml)的糖原分解反应,且肝脏无钙外流。U - 46619诱导的葡萄糖输出和血管收缩对灌注液钙浓度表现出相似的剂量依赖性。因此,U - 46619对灌注大鼠肝脏中的糖原分解和血管收缩具有强大的激动剂作用。目前的研究结果支持这样一种观点,即U - 46619通过肝脏内血管收缩诱导的缺氧间接刺激肝糖原分解。